| SciPort RLP

2023 - 2030

Viktoria 1

Univ.-Prof. Dr. Marcus,
Dr. Slavomir

2023 - 2030

eVERA

Univ.-Prof. Dr. Marcus,
Dr. Slavomir

2023 - 2040

An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas (DAREON™-5) (#1472)

Dr. Jürgen

2023 - 2040

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (SNDX-5613-0700) (#1456)

Univ.-Prof. Dr. Michael

2023 - 2025

Schlafeinleitung durch Lachgas/Sauerstoff-Gasmischung (SELAS)

Prof. Dr. Haralampos

2023 - 2024

Quantitative neurophysiologic PSG-based markers for pre-operative prediction of response to upper airway stimulation for OSA

Prof. Dr. Haralampos

2023 - 2040

A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients with small cell lung cancer (DAREONTM-9) (#1508)

Dr. Jürgen

2023 - 2040

An explorative, open-labeled, phase I trial to evaluate feasibility and safety of eftilagimod alpha (IMP321, a LAG-3Ig fusion protein acting as LAG-3 agonist) in combination with immunotherapeutic, targeted or chemotherapeutic agents or when administered via new routes of application in advanced stage solid tumors (INSIGHT) (#1493)

Dr. Jürgen

2023 - 2025

FIT

Dr. Hakim,
Prof. Dr. Niels,
Univ.-Prof. Dr. Matthias

2023 - 2025

MHC-independent T-cell receptors against the tumor microenvironment

Univ.-Prof. Dr. Thomas,
Prof. Dr. Rienk,
Univ.-Prof. Dr. Matthias,
Dr. Michael

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz